輸液および経口鉄剤の世界市場-注目市場（2024年～2029年）

世界の輸液および経口鉄剤の市場規模は、2023年に76億6,000万米ドルとなりました。同市場は、2029年までに力強い成長を遂げ、CAGR 13.47%で拡大するとみられています。この急成長の主な要因は、世界の鉄欠乏症（ID）および鉄欠乏性貧血（IDA）の有病率の増加と、効果的な治療オプションに関する患者の意識の高まりです。慢性腎臓病（CKD）、心不全、胃腸障害、がんなど、特に外科手術患者において鉄欠乏を引き起こす可能性のある慢性疾患の発生が増加していることも、市場の拡大を後押ししています。

市場成長を促進する主な要因としては、デキストランフリーの鉄治療薬に対する需要の高まりや、透析および非透析の腎臓患者における鉄剤のニーズの高まりが挙げられます。また、より広い適応症と治療成績の向上を目指した、治験中の最新世代の静注・経口鉄剤の開発も、市場の追い風となっています。

Vifor Pharmaのような市場リーダーは、Ferinject（米国ではInjectaferとして販売）やVenoferといった製品で大きく貢献しており、特に透析患者の間で人気を集めています。処方薬とOTC製剤の両方からなる経口鉄剤セグメントは、静脈注射用鉄剤に比べれば緩やかではあるもの、着実に拡大しており、費用対効果の高さから新興国や低所得国で大きな伸びを示しています。

市場の成長は先進国だけにとどまらず、鉄欠乏が深刻な健康上の課題となっているアジア、アフリカ、ラテンアメリカの新興諸国でも著しいです。この成長は、病院薬局の業務革新と小売店の関与によってさらに促進され、消費者のアクセシビリティと認知度を高めています。

病院薬局部門は、鉄剤に特化したサービスを提供しているため、成長が見込まれています。同時に、小売店はすぐに製品を入手でき、専門家による指導が受けられるため、引き続き重要な役割を果たしています。CKD患者における鉄欠乏症の有病率は約70%と推定され、点滴・経口鉄剤による鉄治療の重要な必要性が浮き彫りになっています。

当レポートでは、世界の輸液および経口鉄剤市場について調査し、市場の概要とともに、投与経路別、患者グループ別、流通チャネル別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 輸液および経口鉄剤市場概要

第2章 輸液および経口鉄剤市場

第3章 輸液および経口鉄剤市場の予測収益（2023年～2029年;10億米ドル）

• 世界：投与経路別の予測収益（2023年～2029年;10億米ドル）
• 世界：患者グループ別の予想収益（2023年～2029年;10億米ドル）
• 世界：流通チャネル別の予想収益（2023年～2029年;10億米ドル）
• 世界：用途別の予測収益（2023年～2029年;10億米ドル）

第4章 主要地域の概要

• 北米
• 米国
• カナダ
• 欧州
• ドイツ
• 英国
• フランス
• イタリア
• スペイン
• アジア太平洋
• 日本
• 中国
• オーストラリア
• ラテンアメリカ
• ブラジル
• メキシコ
• アルゼンチン
• 中東・アフリカ
• トルコ
• 南アフリカ
• サウジアラビア

第5章 輸液および経口鉄剤市場の展望と機会

• IVおよび経口鉄剤市場の機会と動向
• IVおよび経口鉄剤市場の促進要因
• IVおよび経口鉄剤市場の抑制要因

第6章 輸液および経口鉄剤業界の概要

• IVおよび経口鉄剤市場-競合情勢
• IVおよび経口鉄剤市場- 主要ベンダーのプロファイル
• IVおよび経口鉄剤市場- その他の著名なベンダー
• IVおよび経口鉄剤市場- 主要な戦略的推奨事項

第7章 付録

List Of Exhibits

LIST OF EXHIBITS

Exhibit 1: Projected Revenues of IV & Oral Iron Drugs in Global ($ Bn)

Exhibit 2: Market Size & Forecast - Intravenous ($ Bn)

Exhibit 3: Market Size & Forecast - Oral ($ Bn)

Exhibit 4: Market Size & Forecast - Adults ($ Bn)

Exhibit 5: Market Size & Forecast - Pediatrics ($ Bn)

Exhibit 6: Market Size & Forecast - Hospital Pharmacies ($ Bn)

Exhibit 7: Market Size & Forecast - Offline Retail Stores

Exhibit 8: Market Size & Forecast - Online Channels ($ Bn)

Exhibit 9: Market Size & Forecast - Nephrology ($ Bn)

Exhibit 10: Market Size & Forecast - Obstetrics & Gynecology ($ Bn)

Exhibit 11: Market Size & Forecast - Surgery ($ Bn)

Exhibit 12: Market Size & Forecast - Gastroenterology ($ Bn)

Exhibit 13: Market Size & Forecast - Oncology ($ Bn)

Exhibit 14: Market Size & Forecast - Heart Failure ($ Bn)

Exhibit 17: Projected Revenues of IV & Oral Iron Drugs in North America ($ Bn)

Exhibit 18: Projected Revenues of IV & Oral Iron Drugs in US ($ Bn)

Exhibit 19: Projected Revenues of IV & Oral Iron Drugs in Canada ($ Bn)

Exhibit 20: Projected Revenues of IV & Oral Iron Drugs in Europe ($ Bn)

Exhibit 21: Projected Revenues of IV & Oral Iron Drugs in Germany ($ Bn)

Exhibit 22: Projected Revenues of IV & Oral Iron Drugs in UK ($ Bn)

Exhibit 23: Projected Revenues of IV & Oral Iron Drugs in France ($ Bn)

Exhibit 24: Projected Revenues of IV & Oral Iron Drugs in Italy ($ Bn)

Exhibit 25: Projected Revenues of IV & Oral Iron Drugs in Spain ($ Bn)

Exhibit 26: Projected Revenues of IV & Oral Iron Drugs in APAC ($ Bn)

Exhibit 27: Projected Revenues of IV & Oral Iron Drugs in Japan ($ Bn)

Exhibit 28: Projected Revenues of IV & Oral Iron Drugs in China ($ Bn)

Exhibit 29: Projected Revenues of IV & Oral Iron Drugs in Australia ($ Bn)

Exhibit 30: Projected Revenues of IV & Oral Iron Drugs in Latin America ($ Bn)

Exhibit 31: Projected Revenues of IV & Oral Iron Drugs in Brazil ($ Bn)

Exhibit 32: Projected Revenues of IV & Oral Iron Drugs in Mexico ($ Bn)

Exhibit 33: Projected Revenues of IV & Oral Iron Drugs in Argentina ($ Bn)

Exhibit 34: Projected Revenues of IV & Oral Iron Drugs in Middle East & Africa ($ Bn)

Exhibit 35: Projected Revenues of IV & Oral Iron Drugs in Turkey ($ Bn)

Exhibit 36: Projected Revenues of IV & Oral Iron Drugs in South Africa ($ Bn)

Exhibit 37: Projected Revenues of IV & Oral Iron Drugs in Saudi Arabia ($ Bn)

List Of Tables

LIST OF TABLES

Table 1: Key Market Trends in IV & Oral Iron Drugs Market

Table 2: Key Market Enablers in IV & Oral Iron Drugs Market

Table 3: Key Market Constraints in IV & Oral Iron Drugs Market

Table 4: Strategic Recommendations in IV & Oral Iron Drugs Market

The global IV and Oral Iron Drugs market, valued at $7.66 billion in 2023, will experience robust growth by 2029, expanding at a CAGR of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, coupled with a heightened awareness among patients about effective treatment options. The market's expansion is further propelled by the rising occurrence of chronic diseases such as Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer, which can lead to iron deficiency, particularly in surgical patients.

Key factors fueling market growth include the growing demand for dextran-free iron therapeutics and the rising need for iron drugs among dialysis and non-dialysis kidney patients. The market also benefits from the development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes.

Market leaders like Vifor Pharma are significantly contributing with products such as Ferinject (marketed as Injectafer in the US) and Venofer, which are gaining traction, especially among dialysis patients. The oral iron drug segment, comprising both prescription and OTC preparations, is expanding steadily, although slower than IV iron drugs, with significant growth in emerging and low-income countries due to their cost-effectiveness.

The market's growth is not just confined to developed nations; it's also significant in developing countries across Asia, Africa, and Latin America, where iron deficiency poses a severe health challenge. This growth is further augmented by innovations in hospital pharmacy practice and retail store involvement, facilitating accessibility and awareness among consumers.

The hospital pharmacies segment is expected to grow due to their specialized services in iron medicines. At the same time, retail stores continue to play a crucial role due to immediate product availability and expert guidance. The prevalence of iron deficiency in CKD patients, which is estimated to be around 70%, highlights the critical need for iron therapy with IV and oral iron drugs.

As the global IV & oral iron drugs market evolves, key vendors like Vifor Pharma, Daiichi Sankyo Group, AMAG Pharmaceuticals, and others focus on product innovations and expanded label approvals to meet the growing demands and adapt to new patient groups. The market, characterized by the presence of global, regional, and local players, is highly competitive with a wide array of branded and generic drug offerings.

KEY HIGHLIGHTS:

• The IV & oral iron drugs market represents a rapidly growing and most effective category of therapeutics that helps individuals with ID & IDA to improve their quality of life.
• By route of administration, the intravenous (IV) segment was valued at $4.40 billion in 2023. This growth mainly results from the expected launch of branded IV iron drugs in new markets and expanded indication approval for existing commercially available brands. One of the primary reasons for this significant growth rate is the increased uptake of branded IV drugs in the US and European markets.
• By patient group, the adult segment is going to witness notable growth during the forecast period. In 2023, the adult segment accounted for 83.33% of the global IV & oral iron drugs market. The segment is dominating the market due to the higher incidence/ prevalence of ID and IDA among elderly people across the world.
• By distribution channel, the hospital pharmacies segment is expected to grow at a significant CAGR. Hospital pharmacies offer iron drugs with adequate discounts and rebates. Thus offering a cost-effective way to minimize the burden on patients and healthcare systems.
• By application, In 2023, the nephrology segment accounted for 60.84% of the global IV & oral iron drugs market. The market for iron drugs in nephrology is increasing faster, and the trend is likely to continue during the forecast period due to the rising prevalence of CKD worldwide. The segment accounted for the largest market share owing to the increasing uptake of iron drugs to treat CKD.
• CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics, and others are some of the leading players currently dominating the global IV & Oral iron drugs market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the IV & Oral Iron Drugs market and to gain access to commercially launched products.

REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST

• Route of Administration
• Intravenous
• Oral
• Patient Group
• Adults
• Pediatrics
• Distribution Channel
• Hospital Pharmacies
• Offline Retail Pharmacies
• Online Channels
• Application
• Nephrology
• Obstetrics & Gynaecology
• Surgery
• Gastroenterology
• Oncology
• Heart Failure
• MARKET STRUCTURE
• Market Dynamics
• Competitive Landscape of IV & Oral Iron Drugs Market
• Key Vendors
• Other Prominent Vendors
• APPENDIX
• Research Methodology
• Abbreviations
• About Arizton

VENDORS LIST

• CSL Vifor
• Daiichi Sankyo
• Covis Pharmaceuticals
• Akebia Therapeutics
• Shield Therapeutics
• Pharmacosmos
• AbbVie
• Sanofi
• AOP Orphan Pharmaceuticals
• Azad Pharmaceuticals
• Pfizer
• Ciron Drugs & Pharmaceuticals
• Rockwell Medical
• Salveo Lifecare
• Sunny Pharmaceuticals
• Zydus LifeSciences
• Nippon Shinyaku
• Alinter Group
• Alora Pharmaceuticals
• DSE Healthcare
• GSK plc

TABLE OF CONTENTS

CHAPTER - 1: IV & Oral Iron Drugs Market Overview

• Executive Summary
• Key Findings

CHAPTER - 2: IV & Oral Iron Drugs Market

• GLOBAL: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)

CHAPTER - 3: IV & Oral Iron Drugs Market Segmentation Data

• GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Billions)
• Intravenous
• Oral
• GLOBAL: Projected Revenue by Patient Group (2023-2029; $Billions)
• Adults
• Pediatrics
• GLOBAL: Projected Revenue by Distribution Channel (2023-2029; $Billions)
• Hospital Pharmacies
• Offline Retail Pharmacies
• Online Channels
• GLOBAL: Projected Revenue by Application (2023-2029; $Billions)
• Nephrology
• Obstetrics & Gynecology
• Surgery
• Gastroenterology
• Oncology
• Heart Failure

CHAPTER - 4: Key Regions Overview

• North America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in US
• Projected Revenue of IV & Oral Iron Drugs Market in Canada
• Europe: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Germany
• Projected Revenue of IV & Oral Iron Drugs Market in UK
• Projected Revenue of IV & Oral Iron Drugs Market in France
• Projected Revenue of IV & Oral Iron Drugs Market in Italy
• Projected Revenue of IV & Oral Iron Drugs Market in Spain
• APAC: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Japan
• Projected Revenue of IV & Oral Iron Drugs Market in China
• Projected Revenue of IV & Oral Iron Drugs Market in Australia
• Latin America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Brazil
• Projected Revenue of IV & Oral Iron Drugs Market in Mexico
• Projected Revenue of IV & Oral Iron Drugs Market in Argentina
• Middle East & Africa: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Turkey
• Projected Revenue of IV & Oral Iron Drugs Market in South Africa
• Projected Revenue of IV & Oral Iron Drugs Market in Saudi Arabia

CHAPTER - 5: IV & Oral Iron Drugs Market Prospects & Opportunities

• IV & Oral Iron Drugs Market Opportunities & Trends
• IV & Oral Iron Drugs Market Drivers
• IV & Oral Iron Drugs Market Constraints

CHAPTER - 6: IV & Oral Iron Drugs Industry Overview

• IV & Oral Iron Drugs Market - Competitive Landscape
• IV & Oral Iron Drugs Market - Key Vendor Profiles
• IV & Oral Iron Drugs Market - Other Prominent Vendors
• IV & Oral Iron Drugs Market - Key Strategic Recommendations

CHAPTER - 7: Appendix

• Research Methodology
• Abbreviations
• About Arizton